2-[[4-[(7-Chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol

Contact：Emma          Tel：+86 15738360906            Email：emma@coreychem.com​

Product Name:2-[[4-[(7-Chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol
CAS:118-42-3
MF:C18H26ClN3O
MW:335.88
EINECS:204-249-8
Mol File:118-42-3.mol

2-[[4-[(7-Chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol Chemical Properties
Melting point:89-91°
Boiling point:516.7±50.0 °C(Predicted)
Density 1.1438 (rough estimate)
refractive index 1.5790 (estimate)
pka14.76±0.10(Predicted)
NIST Chemistry ReferenceHydroxychloroquine(118-42-3)
EPA Substance Registry SystemEthanol, 2-[[4-[(7-chloro-4-quinolinyl)amino]pentyl]ethylamino]- (118-42-3)
2-[[4-[(7-Chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol Usage And Synthesis
Application in Particular DiseasesIn Rheumatic Arthritis:
Hydroxychloroquine lacks the myelosuppressive, hepatic, and renal toxicities seen with some other DMARDs, which simplifies monitoring. Its onset may be delayed for up to 6 weeks, but the drug should not be considered a therapeutic failure until after 6 months of therapy with no response.
Short-term toxicities include GI (nausea, vomiting, diarrhea), ocular (accommodation defects, benign corneal deposits, blurred vision, scotomas, night blindness, preretinopathy), dermatologic (rash, alopecia, skin pigmentation), and neurologic (headache, vertigo, insomnia) effects. Periodic ophthalmologic examinations are necessary for early detection of reversible retinal toxicity.
UsesAntimalarial; suppressant (lupus erythematosus).
DefinitionChEBI: An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used s the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
IndicationsHydroxychloroquine (Plaquenil), like chloroquine, is a 4-aminoquinoline derivative used for the suppressive and acute treatment of malaria. It also has been used for rheumatoid arthritis and discoid and systemic lupus erythematosus. Hydroxychloroquine has not been proved to be more effective than chloroquine. Adverse reactions associated with its use are similar to those described for chloroquine.The drug should not be used in patients with psoriasis or porphyria, since it may exacerbate these conditions.
Clinical UseHydroxychloroquine is approved for the treatment of both systemic and cutaneous lupus erythematosus. Both chloroquine and quinacrine (Atabrine) are also effective in this skin disease. Low-dose chloroquine is used for the therapy of porphyria cutanea tarda in patients in whom phlebotomy has failed or is contraindicated. Other skin diseases in which the drugs are useful (after sunscreens and avoidance of sun exposure) include polymorphous light eruption and solar urticaria.